Antigen Information

General Information of This Antigen (ID: TAR0VKDND)
Antigen Name
Vascular endothelial growth factor A (VEGFA)
Gene Name
VEGFA
Gene ID
7422
Synonym
VEGF; Vascular permeability factor
Sequence
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD
IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM
SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPG
PHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

    Click to Show/Hide
Family
Paired homeobox family
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Also binds the DEAR/FBXW7-AS1 receptor.

    Click to Show/Hide
Uniprot Entry
VEGFA_HUMAN
HGNC ID
HGNC:12680
KEGG ID
hsa:7422
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Bevacizumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
AB-160
Paclitaxel
Undisclosed
Undisclosed
 ADC Info 
Bevacizumab vedotin [1]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Bevacizumab-Compound 9 [2]
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 9 linker
 ADC Info 
Bevacizumab-Compound 17 [2]
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 17 linker
 ADC Info 
Bevacizumab-Compound 25 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 25 linker
 ADC Info 
Bevacizumab-Compound 31 [2]
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 31 linker
 ADC Info 
Bevacizumab-Compound 36 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 36 linker
 ADC Info 
Bevacizumab-Compound 43 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 43 linker
 ADC Info 
Bevacizumab-Compound 49 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 49 linker
 ADC Info 
Bevacizumab-Compound 55 [2]
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 55 linker
 ADC Info 
Bevacizumab-Compound 59 [2]
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 59 linker
 ADC Info 
Bevacizumab-Compound 64 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 64 linker
 ADC Info 
Bevacizumab-Compound 69 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 69 linker
 ADC Info 
Bevacizumab-Compound 74 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 74 linker
 ADC Info 
Bevacizumab-Compound 75 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 75 linker
 ADC Info 
Bevacizumab-Compound 76 [2]
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 76 linker
 ADC Info 
Bevacizumab-Compound 77 [2]
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 77 linker
 ADC Info 
Bevacizumab-Compound 78 [2]
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 78 linker
 ADC Info 
Bevacizumab-Compound 79 [2]
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 79 linker
 ADC Info 
Bevacizumab-Compound 80 [2]
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 80 linker
 ADC Info 
36924655 ADC 32 [3]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
Bevacizumab-DOX-PDT-1 [4]
Doxorubicin; PDT
Undisclosed
Undisclosed
 ADC Info 
Bevacizumab-DOX-PDT-2 [4]
Doxorubicin; PDT
Undisclosed
Undisclosed
 ADC Info 
Bevacizumab fluoresceine 13 [5]
Fluoresceine 13
Undisclosed
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
WO2024140927A1-ADC-F (DAR2) [6]
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
CL2A
 ADC Info 
WO2024140927A1-ADC-G (DAR2) [6]
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
KSI-601 [7]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
CBT-005 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
References
Ref 1 Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023 Aug;137:106575. doi: 10.1016/j.bioorg.2023.106575. Epub 2023 Apr 26.
Ref 2 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 3 Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads
Ref 4 Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy
Ref 5 Exploring the Chemical Properties and Medicinal Applications of Tetramethylthiocycloheptyne Sulfoximine Used in Strain-Promoted Azide-Alkyne Cycloaddition Reactions
Ref 6 Use of hydroxypropyl-β-cyclodextrin in stabilizing antibody-drug conjugate formulations
Ref 7 Kodiak biopharmaceutical company product pipeline
Ref 8 Cloudbreak pharmaceutical company product pipeline